Group A, C Meningococcal Polysaccharide Conjugate Vaccine, Freeze-dried is the second product developed independently by Walvax. Walvax obtained the Drug Registration Approval issued by the State Food and Drug Administration on January 4th, 2009 (No.: 2009S00135, Drug Approval No.: Guoyao Zhunzi S20090003). The product was on market officially in September 2009.
The vaccine is a lyophilized vaccine of Meningococcal 29201 strain capsular polysaccharide antigen via polysaccharide activation and derivatization covalently bound to tetanus toxoid protein. The meningococcal capsular polysaccharide is obtained from Neisseria meningitides (Meningococcus) serogroup A and C individually through fermentation and purification. The group A and C conjugates are mixed at certain proportion and lyophilized with the proper stabilizer. The vaccine is indicated for infants from the age of 3 months to 5 years preventing diseases caused by Meningococcal Group A or C, such as cerebrospinal meningitis and septicemia.